(Q37008621)

17 August 2017

1 reference

title

The role of the CTLA4 blockade in the treatment of malignant melanoma (English)

1 reference

17 August 2017

Lee D Cranmer

1

1 reference

17 August 2017

Evan Hersh

series ordinal

2

1 reference

17 August 2017

publication date

1 October 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

25

1 reference

17 August 2017

issue

7

1 reference

17 August 2017

page(s)

613-631

1 reference

Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Active-specific immunization against melanoma: is the problem at the receiving end?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4 (CD152) and its involvement in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Expression of CTLA-4 by human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

21 January 2018

The B7-CD28 superfamily

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4 can function as a negative regulator of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4 ligation blocks CD28-dependent T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Differential expression of CTLA-4 among T cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Regulatory T cells and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

The interaction properties of costimulatory molecules revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CD28, CTLA-4 and their ligands: who does what and to whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4 regulates cell cycle progression during a primary immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

PI3K/Akt/mTOR pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4: a negative regulator of autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Differential requirement for CD28/CTLA-4-CD80/CD86 interactions in drug-induced type 1 and type 2 immune responses to trinitrophenyl-ovalbumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Developing aptamers into therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA4 polymorphisms are associated with vitiligo, in patients with concomitant autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CD25(+)CD4(+) regulatory T cells exert in vitro suppressive activity independent of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

CTLA-4-/- mice display T cell-apoptosis resistance resembling that ascribed to autoimmune-prone non-obese diabetic (NOD) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701522315

10.1080/07357900701522315

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference